Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial

Js Smolen; P Emery; Gianfranco Ferraccioli; W Samborski; F Berenbaum; Or Davies; W Koetse; O Purcaru; B Bennett; H. Burkhardt

doi:10.1136/annrheumdis-2013-204632

Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial

Js Smolen^*, P Emery, Gianfranco Ferraccioli, W Samborski, F Berenbaum, Or Davies, W Koetse, O Purcaru, B Bennett, H. Burkhardt

^*Autore corrispondente per questo lavoro

Goethe University Frankfurt

Risultato della ricerca: Contributo in rivista › Articolo

68 Citazioni (Scopus)

Abstract

This 52-week, randomised, double-blind phase IIIb study assessed efficacy and safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients with low to moderate disease activity, and stopping therapy in patients in sustained remission.

Lingua originale	Inglese
pagine (da-a)	843-850
Numero di pagine	8
Rivista	Annals of the Rheumatic Diseases
Volume	74
Numero di pubblicazione	5
DOI	https://doi.org/10.1136/annrheumdis-2013-204632
Stato di pubblicazione	Pubblicato - 2015
Pubblicato esternamente	Sì

All Science Journal Classification (ASJC) codes

Reumatologia
Immunologia e Allergia
Immunologia
Biochimica, Genetica, Biologia Molecolare Generali

Keywords

Adolescent
Anti-TNF
Antibodies
Antirheumatic Agents
Arthritis
Certolizumab Pegol
Combination
DMARDs (biologic)
Disease Activity
Double-Blind Method
Drug Therapy
Humanized
Immunoglobulin Fab Fragments
Immunosuppressive Agents
Maintenance Chemotherapy
Methotrexate
Middle Aged
Monoclonal
Polyethylene Glycols
Remission Induction
Rheumatoid
Rheumatoid Arthritis
Severity of Illness Index
Treatment Outcome
Young Adult

Accesso al documento

10.1136/annrheumdis-2013-204632

Altri file e collegamenti

Cita questo

Smolen, J., Emery, P., Ferraccioli, G., Samborski, W., Berenbaum, F., Davies, O., Koetse, W., Purcaru, O., Bennett, B., & Burkhardt, H. (2015). Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Annals of the Rheumatic Diseases, 74(5), 843-850. https://doi.org/10.1136/annrheumdis-2013-204632

@article{d4f1131c432d4f20bff04f2e5a64f2f8,

title = "Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial",

abstract = "This 52-week, randomised, double-blind phase IIIb study assessed efficacy and safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients with low to moderate disease activity, and stopping therapy in patients in sustained remission.",

keywords = "Adolescent, Anti-TNF, Antibodies, Antirheumatic Agents, Arthritis, Certolizumab Pegol, Combination, DMARDs (biologic), Disease Activity, Double-Blind Method, Drug Therapy, Humanized, Immunoglobulin Fab Fragments, Immunosuppressive Agents, Maintenance Chemotherapy, Methotrexate, Middle Aged, Monoclonal, Polyethylene Glycols, Remission Induction, Rheumatoid, Rheumatoid Arthritis, Severity of Illness Index, Treatment Outcome, Young Adult, Adolescent, Anti-TNF, Antibodies, Antirheumatic Agents, Arthritis, Certolizumab Pegol, Combination, DMARDs (biologic), Disease Activity, Double-Blind Method, Drug Therapy, Humanized, Immunoglobulin Fab Fragments, Immunosuppressive Agents, Maintenance Chemotherapy, Methotrexate, Middle Aged, Monoclonal, Polyethylene Glycols, Remission Induction, Rheumatoid, Rheumatoid Arthritis, Severity of Illness Index, Treatment Outcome, Young Adult",

author = "Js Smolen and P Emery and Gianfranco Ferraccioli and W Samborski and F Berenbaum and Or Davies and W Koetse and O Purcaru and B Bennett and H. Burkhardt",

year = "2015",

doi = "10.1136/annrheumdis-2013-204632",

language = "English",

volume = "74",

pages = "843--850",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "London, United Kingdom: BMJ / British Medical Journal Publishing Group",

number = "5",

}

Smolen, J, Emery, P, Ferraccioli, G, Samborski, W, Berenbaum, F, Davies, O, Koetse, W, Purcaru, O, Bennett, B & Burkhardt, H 2015, 'Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial', Annals of the Rheumatic Diseases, vol. 74, n. 5, pagg. 843-850. https://doi.org/10.1136/annrheumdis-2013-204632

TY - JOUR

T1 - Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial

AU - Smolen, Js

AU - Emery, P

AU - Ferraccioli, Gianfranco

AU - Samborski, W

AU - Berenbaum, F

AU - Davies, Or

AU - Koetse, W

AU - Purcaru, O

AU - Bennett, B

AU - Burkhardt, H.

PY - 2015

Y1 - 2015

N2 - This 52-week, randomised, double-blind phase IIIb study assessed efficacy and safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients with low to moderate disease activity, and stopping therapy in patients in sustained remission.

AB - This 52-week, randomised, double-blind phase IIIb study assessed efficacy and safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients with low to moderate disease activity, and stopping therapy in patients in sustained remission.

KW - Adolescent

KW - Anti-TNF

KW - Antibodies

KW - Antirheumatic Agents

KW - Arthritis

KW - Certolizumab Pegol

KW - Combination

KW - DMARDs (biologic)

KW - Disease Activity

KW - Double-Blind Method

KW - Drug Therapy

KW - Humanized

KW - Immunoglobulin Fab Fragments

KW - Immunosuppressive Agents

KW - Maintenance Chemotherapy

KW - Methotrexate

KW - Middle Aged

KW - Monoclonal

KW - Polyethylene Glycols

KW - Remission Induction

KW - Rheumatoid

KW - Rheumatoid Arthritis

KW - Severity of Illness Index

KW - Treatment Outcome

KW - Young Adult

KW - Adolescent

KW - Anti-TNF

KW - Antibodies

KW - Antirheumatic Agents

KW - Arthritis

KW - Certolizumab Pegol

KW - Combination

KW - DMARDs (biologic)

KW - Disease Activity

KW - Double-Blind Method

KW - Drug Therapy

KW - Humanized

KW - Immunoglobulin Fab Fragments

KW - Immunosuppressive Agents

KW - Maintenance Chemotherapy

KW - Methotrexate

KW - Middle Aged

KW - Monoclonal

KW - Polyethylene Glycols

KW - Remission Induction

KW - Rheumatoid

KW - Rheumatoid Arthritis

KW - Severity of Illness Index

KW - Treatment Outcome

KW - Young Adult

UR - https://publicatt.unicatt.it/handle/10807/71518

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84926623879&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84926623879&origin=inward

U2 - 10.1136/annrheumdis-2013-204632

DO - 10.1136/annrheumdis-2013-204632

M3 - Article

SN - 0003-4967

VL - 74

SP - 843

EP - 850

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 5

ER -

Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo